Mechanism of Intravenous Immune Globulin Therapy in Antibody-Mediated Autoimmune Diseases
- 21 January 1999
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 340 (3) , 227-228
- https://doi.org/10.1056/nejm199901213400311
Abstract
For more than two decades, the intravenous administration of high doses of IgG pooled from the plasma of healthy donors (immune globulin therapy, also known as “IVIg”) has benefited patients with a variety of autoimmune disorders. Although its mechanism of action is not known, immune globulin is accepted as an effective and convenient alternative to plasmapheresis for treating diseases that are thought to be mediated by pathogenic autoantibodies or immune complexes.1 It is used increasingly to treat neurologic diseases such as inflammatory demyelinating neuropathies, multifocal motor neuropathy, inflammatory myopathies, myasthenia gravis, and the Lambert–Eaton syndrome. The efficacy of immune globulin . . .Keywords
This publication has 8 references indexed in Scilit:
- FcRn: the MHC class I-related receptor that is more than an IgG transporterImmunology Today, 1997
- IgG Biosynthesis: No “Immunoregulatory Feedback”Blood, 1997
- Intravenous Immune Globulin Therapy for Neurologic DiseasesAnnals of Internal Medicine, 1997
- The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.Proceedings of the National Academy of Sciences, 1996
- Elimination of Infectious Antigens and Increase of IgG Catabolism as Possible Modes of Action of IVIgJournal of Autoimmunity, 1993
- Hormonal control of intestinal Fc receptor gene expression and immunoglobulin transport in suckling rats.Journal of Clinical Investigation, 1993
- A Theoretical Model of γ-Globulin CatabolismNature, 1964
- Relationship Between γ-Globulin Metabolism and Low Serum γ-Globulin in Germfree MiceThe Journal of Immunology, 1964